Techniques used for protein expression proteomics study include:

PolyAcrylamide Gel Electrophoresis (PAGE)

Gene Expression Analysis (indirectly related to proteomics)

A research team is developing a gene therapy approach using CRISPR-Cas9 to correct a point mutation causing sickle cell disease. They must decide between two strategies: (A) correcting the mutation in hematopoietic stem cells ex vivo, or (B) in vivo correction in bone marrow. Considering molecular physiology principles, what is the most significant advantage of strategy A over strategy B?

Strategy A allows for screening and selection of successfully edited cells before transplantation, minimizing off-target effects

Strategy A requires lower doses of viral vectors

Strategy A produces faster clinical improvement

Strategy A is less expensive to implement

A novel drug is designed to treat a genetic disorder caused by a nonsense mutation in the dystrophin gene. The drug works by allowing the ribosome to skip over the premature stop codon and continue translation. Evaluation of this therapeutic strategy reveals partial restoration of dystrophin protein with 60% of normal length but sufficient function. What is the most critical molecular consideration in determining if this approach will be clinically beneficial?

Whether the truncated protein retains the actin-binding domain and maintains membrane stability

Whether the drug prevents degradation of dystrophin mRNA

Whether the drug enhances ribosomal binding to the start codon

Whether the drug increases transcription of the dystrophin gene

Post-Translational Modifications for FMGE: High-Yield Physiology Lessons

Introduction to PTMs - Protein Polish & Purpose

Covalent chemical alterations to proteins after their synthesis on ribosomes.
"Protein polish": Critical for transforming nascent polypeptides into mature, functional proteins.
Vastly expand proteome complexity; >200 distinct PTM types identified.
Essential for:
- Regulating protein activity (e.g., enzyme kinetics).
- Determining subcellular localization.
- Modulating protein-protein/protein-ligand interactions.
- Controlling protein half-life and degradation pathways.
Occur in various cellular locations like ER, Golgi, cytoplasm.

⭐ PTMs are fundamental to cellular signaling, allowing rapid responses to stimuli.

Major PTMs I - Kinase Kisses & Sugar Coats

Phosphorylation: Reversible addition of phosphate ($PO_4^{3-}$)

Enzymes: Kinases (add $PO_4^{3-}$ from ATP), Phosphatases (remove $PO_4^{3-}$).
Targets: -OH of Ser, Thr, Tyr (key in eukaryotes).
Functions: Regulates protein activity (on/off), signaling (MAPK), metabolism.

⭐ Protein kinases constitute one of the largest enzyme families, phosphorylating ~30% of all human proteins.

Glycosylation: Covalent attachment of oligosaccharides (sugars).

Functions: Protein folding, stability, cell adhesion, immunity, signaling.
Types:
- N-linked:
  - To: Asn in Asn-X-Ser/Thr (X ≠ Pro).
  - Location: ER (core, on dolichol-P) → Golgi (modify).
  - Example: Immunoglobulins.
- O-linked:
  - To: Ser, Thr (-OH).
  - Location: Golgi, cytoplasm, nucleus.
  - Example: ABO antigens, mucins. 📌 Mnemonic: N-linked to AsparagiNe. O-linked to -OH of Ser/Thr.

Major PTMs II - Tag, Tuck & Tweak

Ubiquitination: Attaching ubiquitin protein to targets.
- Pathway: 📌 E1 (activates Ub), E2 (conjugates Ub), E3 (ligase, specificity).

-   **Functions**: K48-polyUb → proteasomal degradation. MonoUb/K63-polyUb → signaling, DNA repair, endocytosis.
> ⭐ Bortezomib, a proteasome inhibitor, treats multiple myeloma by preventing degradation of pro-apoptotic factors.

Acetylation: Adds acetyl ($CH_3CO-$) to lysine.
- Enzymes: Histone Acetyltransferases (HATs) add; Histone Deacetylases (HDACs) remove.
- Effect: Neutralizes lysine's (+) charge → loosens chromatin (euchromatin) → ↑ gene transcription.
Methylation: Adds methyl ($-CH_3$) to lysine/arginine.
- Enzymes: Methyltransferases add; Demethylases remove.
- Effect: Context-dependent; H3K4me3 → active transcription; H3K9me3/H3K27me3 → repressive. DNA methylation (cytosine) → gene silencing.

PTMs in Disease & Therapy - Clinical Connections

Pathogenesis:
- Cancer: Dysregulated phosphorylation (kinases like EGFR), ubiquitination (p53, cyclins), histone PTMs (acetylation, methylation).
- Neurodegeneration: Tau hyperphosphorylation (Alzheimer's), α-synuclein PTMs (Parkinson's), huntingtin PTMs (Huntington's).
- Diabetes: Non-enzymatic glycosylation → Advanced Glycation End-products (AGEs) → complications.
- Cystic Fibrosis: CFTR protein misfolding (glycosylation defects).
- Inflammation: Altered SUMOylation, nitrosylation.
Biomarkers:
- $HbA1c$: Glycated hemoglobin for diabetes monitoring (long-term glucose).
- Phosphorylated STAT3 (pSTAT3): Cancer prognosis.
- Circulating tumor DNA (ctDNA) PTMs: Emerging.
Therapeutic Targets:
- Kinase inhibitors: Imatinib (BCR-ABL in CML), erlotinib (EGFR in lung cancer).
- Proteasome inhibitors: Bortezomib (multiple myeloma) - targets ubiquitination pathway.
- HDAC inhibitors: Vorinostat (lymphoma) - targets acetylation.
- Monoclonal antibodies against PTM-modified proteins.
⭐ Imatinib, a tyrosine kinase inhibitor targeting the BCR-ABL fusion protein (a result of PTM pathway dysregulation), revolutionized CML treatment. oka

High-Yield Points - ⚡ Biggest Takeaways

Phosphorylation by kinases (vs. phosphatases) critically regulates enzyme activity and cell signaling.

Glycosylation: N-linked (ER, Asn) and O-linked (Golgi, Ser/Thr) affect protein folding, stability, and targeting.

Ubiquitination: Polyubiquitin signals proteasomal degradation; monoubiquitin has other regulatory roles.

Histone acetylation by HATs activates gene transcription; HDACs reverse this.

Collagen synthesis requires Vitamin C for proline/lysine hydroxylation.

Clotting factor activation needs Vitamin K for gamma-carboxylation of glutamate.

Continue reading on Oncourse

CONTINUE READING — FREE

or get the app

App Store|Google Play